Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVANEC: Bevacizumab + Folfiri in Advanced Neuroendocrine Carcinoma
NCT02820857Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2017
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Proportion of patients alive at 6 months. Started Sep 2017; status: completed.
02
Drugs
bevacizumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT02820857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820857.